IL209967A - Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl - Google Patents

Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl

Info

Publication number
IL209967A
IL209967A IL209967A IL20996710A IL209967A IL 209967 A IL209967 A IL 209967A IL 209967 A IL209967 A IL 209967A IL 20996710 A IL20996710 A IL 20996710A IL 209967 A IL209967 A IL 209967A
Authority
IL
Israel
Prior art keywords
ctl
lymphocyte
cytotoxic
peptides
induce
Prior art date
Application number
IL209967A
Other languages
English (en)
Hebrew (he)
Other versions
IL209967A0 (en
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL209967A0 publication Critical patent/IL209967A0/en
Publication of IL209967A publication Critical patent/IL209967A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL209967A 2008-06-19 2010-12-13 Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl IL209967A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7406208P 2008-06-19 2008-06-19
US19759908P 2008-10-28 2008-10-28
PCT/JP2009/002771 WO2009153992A1 (en) 2008-06-19 2009-06-18 Cdca1 epitope peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
IL209967A0 IL209967A0 (en) 2011-02-28
IL209967A true IL209967A (en) 2015-09-24

Family

ID=41433910

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209967A IL209967A (en) 2008-06-19 2010-12-13 Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl

Country Status (16)

Country Link
US (2) US9387238B2 (enExample)
EP (1) EP2303912B1 (enExample)
JP (1) JP5640262B2 (enExample)
KR (2) KR20160119264A (enExample)
CN (1) CN102119171B (enExample)
AU (1) AU2009261382B2 (enExample)
BR (1) BRPI0914782B1 (enExample)
CA (1) CA2728268C (enExample)
DK (1) DK2303912T3 (enExample)
ES (1) ES2658842T3 (enExample)
IL (1) IL209967A (enExample)
MX (1) MX2010014044A (enExample)
RU (1) RU2502740C2 (enExample)
SG (1) SG191680A1 (enExample)
TW (1) TWI526219B (enExample)
WO (1) WO2009153992A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
CN101835892B (zh) 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 Cdca1肽和包含cdca1肽的药剂
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
MX359234B (es) * 2011-11-11 2018-09-20 Hutchinson Fred Cancer Res Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
CN118221800A (zh) 2013-08-05 2024-06-21 伊玛提克斯生物技术有限公司 针对多种肿瘤例如包括nsclc在内的肺癌的新型免疫疗法
SG11201700839SA (en) * 2014-08-04 2017-03-30 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
US20180200325A1 (en) 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
EP0983357A1 (en) 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
PL354093A1 (en) 1999-06-30 2003-12-29 Corixa Corporationcorixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1265582A2 (en) 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2415544A1 (en) 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1519736A2 (en) 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
DE60327786D1 (de) * 2002-09-12 2009-07-09 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP2006500946A (ja) 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 精巣精上皮腫の診断方法
CA2500521A1 (en) * 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2007527193A (ja) 2002-12-10 2007-09-27 アンドキューブ ソシエタ パー アクシオン シンプリフィー ケモカインに対する核受容体としてのｔｈａｐタンパク質と、転写調節、細胞増殖、および細胞分化におけるその役割
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
TW200533376A (en) 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
EP2311986B1 (en) * 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
JP5150855B2 (ja) * 2005-07-29 2013-02-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
CN101835892B (zh) * 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 Cdca1肽和包含cdca1肽的药剂
CN104356225B (zh) 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH

Also Published As

Publication number Publication date
KR20160119264A (ko) 2016-10-12
EP2303912B1 (en) 2018-01-03
RU2502740C2 (ru) 2013-12-27
IL209967A0 (en) 2011-02-28
US20110189214A1 (en) 2011-08-04
US9387238B2 (en) 2016-07-12
WO2009153992A1 (en) 2009-12-23
TW201000120A (en) 2010-01-01
SG191680A1 (en) 2013-07-31
US20160272692A1 (en) 2016-09-22
AU2009261382B2 (en) 2013-08-15
US10711047B2 (en) 2020-07-14
KR20110031314A (ko) 2011-03-25
AU2009261382A1 (en) 2009-12-23
RU2011101709A (ru) 2012-07-27
KR101705011B1 (ko) 2017-02-23
DK2303912T3 (en) 2018-03-12
BRPI0914782B1 (pt) 2021-08-31
EP2303912A4 (en) 2012-08-29
BRPI0914782A2 (pt) 2016-07-26
CN102119171B (zh) 2014-08-06
CA2728268A1 (en) 2009-12-23
CA2728268C (en) 2017-11-07
EP2303912A1 (en) 2011-04-06
TWI526219B (zh) 2016-03-21
JP5640262B2 (ja) 2014-12-17
JP2011524737A (ja) 2011-09-08
CN102119171A (zh) 2011-07-06
ES2658842T3 (es) 2018-03-12
MX2010014044A (es) 2011-03-03

Similar Documents

Publication Publication Date Title
IL209967A (en) Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl
IL275854A (en) Pharmaceutical composition and its administration
ZA201102645B (en) Method for delivering a pharmaceutical composition to patient in need thereof
HUE052874T2 (hu) Módosított hatóanyagleadású gyógyszerkészítmény
ZA201304728B (en) Boronate ester conpoundds and pharmaceutical compositions thereof
SI2393474T1 (sl) Farmacevtski sestavki, ki vsebujejo imidazokinolin(amine) in njihovi derivati, primerni za lokalno administracijo
ZA201207068B (en) Formulations for oral delivery of adsorbents in the gut
IL203292A (en) History of n-indazolil affluent, process for preparation, intermediates obtained in this process and pharmacological preparations containing the history
IL215780A (en) Acetidinyl Diamides, Pharmaceuticals containing them and their uses
PT2344198T (pt) Preparações farmacêuticas à base de lípidos para aplicação tópica
IL199554B (en) Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs
PT2152195E (pt) Produto farmacêutico peptídico para distribuição oral
EP2143424A4 (en) ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA200908019B (en) Controlled release pharmaceutical compositions for prolonged effect
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
EP2591773A4 (en) TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
ZA201100615B (en) Appetising medicament for oral administration in solid form
PL2154966T3 (pl) Benzoimidazole i ich kompozycje farmaceutyczne
ZA201205103B (en) Pharmaceutical composition comprising oligopeptides,preferably cilengitide
IL215498A0 (en) Oxadiazole derivatives and pharmaceutical compositions containing them
IL218539A (en) Annotated 4,1-Androsteadian-3-Oxo-9,6-Dihlo-16-Isoxazolidine-17-Noble N-Converted
IL210393A0 (en) Administration regime for nitrocatechols
LT2394648T (lt) Farmacinė kompozicija vartojimui per burną
ZA201204619B (en) Pharmaceutical composition comprising vitamin d analogue and cosolventsurfactant mixture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed